- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05921006
Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects
July 5, 2023 updated by: Nanjing Ruijie Pharma Co., Ltd.
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Oral Doses of RJ4287 in Healthy Volunteers
A Randomized Study of RJ4287 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Doses in Healthy Volunteers
Study Overview
Study Type
Interventional
Enrollment (Estimated)
98
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhenning Li, MD
- Phone Number: 0086-025-52391708
- Email: znli@rjpharma.com
Study Locations
-
-
Anhui
-
Bengbu, Anhui, China, 233004
- Recruiting
- The First Affiliated Hospital of Bengbu Medical College
-
Contact:
- Huan Zhou, PhD
- Phone Number: 0088-13665527160
- Email: zhouhuanbest@vip.163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male and Female between 18 and 55 years old,inclusive
- Body weight >50 kg for Male and >45 kg for Female with a body mass index BMI between 19-28 kg/m2(inclusive)
- Female subjects of childbearing potential who have had no unprotected sex within 14 days prior to screening and who have had a negative pregnancy test during the screening period; subjects (including partners) who have no plans for pregnancy, sperm donation or egg donation and are willing to use effective contraception from the time of informed consent until 6 months after administration of the test product;
- The subject must be willing and able to provide written informed consent
Exclusion Criteria:
- History of thyroid disorder or abnormal thyroid function tests at screening
- Abnormal abdominal ultrasound findings with clinical significance
- Subjects with any of the following laboratory tests at screening or baseline were not eligible for enrollment in this study: 1) Glutamic transaminase (AST), glutamic aminotransferase (ALT) or direct bilirubin above the upper limit of the reference range at screening; 2) Positive screening for HIV antibodies, hepatitis B surface antigen, hepatitis C antibodies, syphilis antibodies ECG QTc > 450 ms, QRS > 110 ms, intermittent bundle branch block, frequent premature atrial or ventricular contractions at the time of screening, or any person who is considered clinically significant by the investigator; 4) A routine blood test with a white blood cell count, neutrophil count and lymphocyte count outside the normal reference range at screening and judged clinically significant by the investigator; 5) A kidney disease diet adjustment ( MDRD) formula calculated with an estimated glomerular filtration rate (eGFR) < 90 mL
- Sensitivity to thyroid medication or history of sensitivity to a similar study drug(eg.MGL-3196)
- History of sensitivity to a similar study drug
- Major surgical procedure, previous gastrointestinal surgery, vagotomy, bowel resection or any surgical procedure that may interfere with peristalsis, pH or absorption in the gastrointestinal tract within 6 months prior to screening
- Subjects who, in the judgement of the investigator, have a condition that affects the absorption, distribution, metabolism and excretion of the drug (e.g. gastrointestinal dysfunction, peptic ulcer, gastrointestinal surgery, etc.) or who are unable to comply with a uniform diet during the trial
- Taken any prescription medication, over-the-counter medication, any vitamin product or herbal remedy within 1 month prior to screening
- Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results interpretation
- History of regular use nicotine or alcohol,unable to abstain from smoking and alcohol during the trial
- Previous blood donation or blood loss of more than 400 mL within 3 months prior to taking the study drug
- Had consumed a special diet (including popcorn, dragon fruit, mango, grapefruit, orange, etc.) or alcohol within 2 weeks before taking the study drug, or had strenuous exercise
- Taken an experimental drug or other experimental treatment within 3 months prior to screening, or being involved in any other interventional clinical trial
- Nursing female subjects
- Any other condition that, in the opinion of the investigator or sponsor, makes the subject unsuitable for inclusion in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RJ4287 Tablets
single-dose or Multiple-doses, ascending dosing groups (cohorts) will be evaluated
|
Oral,tablets,Once daily for 14 days
|
Placebo Comparator: Placebo
Single or multiple doses of Placebo
|
Oral,tablets,Once daily daily for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: 1 month
|
Safety measurements will include vital signs, hematology, blood chemistry, blood pressure and other readouts.
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics parameters of blood
Time Frame: 2 weeks
|
To measure the plasma concentration of RJ4287 in single and multiple doses
|
2 weeks
|
Pharmacokinetics parameters of urine
Time Frame: 2 weeks
|
Accumulated excretion
|
2 weeks
|
Pharmacokinetics parameters of faeces
Time Frame: 2 weeks
|
Accumulated excretion
|
2 weeks
|
Change in lipid / lipoprotein levels from baseline through Day 14 in Multiple Dose
Time Frame: 2 weeks
|
compare with placebo
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11.
- Alkhouri N. Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196). Expert Opin Investig Drugs. 2020 Feb;29(2):99-101. doi: 10.1080/13543784.2020.1708899. Epub 2019 Dec 25. No abstract available.
- Taub R, Chiang E, Chabot-Blanchet M, Kelly MJ, Reeves RA, Guertin MC, Tardif JC. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013 Oct;230(2):373-80. doi: 10.1016/j.atherosclerosis.2013.07.056. Epub 2013 Aug 21.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 13, 2023
Primary Completion (Estimated)
December 1, 2023
Study Completion (Estimated)
December 1, 2023
Study Registration Dates
First Submitted
June 15, 2023
First Submitted That Met QC Criteria
June 25, 2023
First Posted (Actual)
June 27, 2023
Study Record Updates
Last Update Posted (Actual)
July 6, 2023
Last Update Submitted That Met QC Criteria
July 5, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- RJ4287001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Safety
-
University of DundeeNHS Tayside; NHS FifeCompleted
-
Entera Bio Ltd.Completed
-
West China HospitalCompleted
-
Prolong PharmaceuticalsTerminated
-
SignPath Pharma, Inc.Completed
-
Madrigal Pharmaceuticals, Inc.Completed
-
Mahidol UniversitySiriraj HospitalUnknown
-
Northwestern UniversityActive, not recruiting
-
Madrigal Pharmaceuticals, Inc.Completed
-
University of Missouri-ColumbiaNational Center for Complementary and Integrative Health (NCCIH); University...Completed